NCT00284947View on ClinicalTrials.gov

Safety and Efficacy of Basiliximab in Calcineurin Inhibitor Intolerant Long-term Kidney Transplant Recipients Treated With Mycophenolic Acid and Steroids

PHASE4CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 31, 2006

Primary Completion Date

December 31, 2008

Study Completion Date

December 31, 2008

Conditions
Kidney TransplantationAdverse Effects
Interventions
DRUG

basiliximab

40 mg once every 28 days intravenously for 24 weeks

DRUG

MMF/EC-MPS

1g MMF or 720mg EC-MPS p.o twice daily

DRUG

Corticosteroids

Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY